ApoPharma Inc.

Data Safety Monitoring Board Communication

Date: 26 Aug 2015

TO: TIRCON2012V1 study Investigators

FROM: Dr. Anna Rozova, Director, Medical Safety, ApoPharma Inc.

RE: Clinical study protocol, TIRCON2012V1: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate-kinase associated neurodegeneration (PKAN)

DSMB safety review meeting of 19 Aug 2015

The fifth interim review meeting of the independent Data Safety Monitoring Board (DSMB) for the clinical study, TIRCON2012V1, was held on 19 Aug 2015.

The meeting was scheduled and held according to the planned periodic review of safety data. The review encompassed the safety data collected from the beginning of the study until the cut-off period of 09 Jul 2015 and any late-breaking safety information received between the cut-off point and the date of the meeting.

The DSMB reviewed the above-referenced data. The DSMB noted a concern about three (3) patients who show a decreasing trend in haemoglobin and recommended for ApoPharma to inform the study investigators of the trend and attempt to determine potential underlying causes.

The DSMB did not identify any issues requiring premature unblinding, suspension or termination of the study, and recommended the continuation of the study.

The next planned interim review meeting will be in Feb 2016.